The Metsera deal is about winning the obesity drugs' market that’s expected to reach US$100 billion by 2030. Read more at ...

Pfizer Inc. has agreed to buy Metsera Inc. for $10 billion, surpassing Novo Nordisk in a competitive bidding war. Details of ...

Pfizer appeared to have locked up the acquisition in September before Novo jumped in last week with an unsolicited offer, ...

Metsera, an obesity drug developer, has accepted a $10 billion acquisition offer from pharmaceutical giant Pfizer, potentially concluding a bidding war with Novo Nordisk.

Pfizer Inc. has agreed to buy Metsera Inc. in a $10 billion deal, following a tumultuous bidding war with Novo Nordisk A/S ...

Metsera said that Pfizer will pay up to US$86.25 a share, including US$65.60 a share in cash initially, plus potential additional payments of up to US$20.65 a share for hitting certain milestones.

After a bidding war erupted between Pfizer and Novo Nordisk over the fledgling obesity drug maker, Metsera decided to side with its original suitor.

OBESITY drug developer Metsera said on Friday that it had accepted Pfizer’s US$10 billion acquisition offer, in what could ...

Pfizer has won the bidding war against Novo Nordisk to acquire obesity-drug biotech Metsera. The pharma giant upped its offer ...

Pfizer has clinched a deal worth up to $10bn to buy weight-loss start-up Metsera, capping a dramatic takeover battle after ...

Revised transaction values Metsera at up to $86.25 per share Metsera's Board of Directors unanimously recommends that Metsera stockholders approve the ...

Pfizer prevailed over Novo Nordisk after an unusual bidding war for the weight-loss startup.